RCT of metformin and lifestyle intervention in metabolic syndrome, results not reported
This was a Phase III randomized controlled trial in people with metabolic syndrome designed to test whether metformin and comprehensive lifestyle changes (moderate physical activity, Mediterranean/macrobiotic diet with calorie and protein restriction) prevent age-related chronic diseases. The abstract describes only the study design and aims; no results or outcomes are reported.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Sep 28, 2021 · Discovered: Sep 15, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- Men and women with Metabolic syndrome (MetS)
- Primary outcome
- Prevention of age-related chronic non-communicable diseases (ArCD)
- Effect size
- —
- Significance
- Not reported
- Journal
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Published
- Sep 28, 2021
Sources
Primary source
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano ↗Clinical trial
Source versions
Assessment history
9/23/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.